Tagged with clinic

CRO Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation in the local life science industry.   What have been some of the main changes for PAREXEL in Korea since…

CRO A senior director for Icon plc discusses Argentina’s strengths and weaknesses as a venue for clinical trials, the role the market plays in a global clinical trial strategy, and Icon’s ambitions for growth in the region.   What are Argentina’s strategic advantages in terms of clinical trial strategy? Argentina in…

clinical trials Dr. Wanda Dobrzanski discusses Argentina’s potential and attractiveness as a clinical research environment and the biggest challenges facing local and global CROs in Argentina.   How has political and popular opposition to clinical trials in Argentina changed over the last five years? Five years ago, the perception of clinical trials…

CRO The opening of the Mexican Social Security Institute (IMSS) to clinical research is a unique opportunity for Mexico to step up on the international scenario for clinical trials. The CEO of Innovare explains how the company is betting on Mexico to conduct clinical R&D and help companies bring innovative drugs to…

stem cell The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative medicine to revolutionize a variety of healthcare practices. Dr. Yang, to begin, could you please introduce yourself and MEDIPOST to…

clinical research The head of Management Center for the North West Africa of a large multinational speaks out about the defining characteristics of the Algerian pharmaceutical market and discusses the importance of training local medical practitioners in clinical research techniques and methodologies. Now, you are the Head of the Management Center for…

rare diseases The country manager of a leading German chemical and pharmaceutical company sheds light on her company’s activities in the rare diseases segment and speaks about the multiple benefits of promoting home care and greater patient autonomy. You are known for your medicines against diseases that are often neglected, such as…

clinical trials Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers? 2014 was the 55th anniversary of Ahngook’s foundation. I have worked for Ahngook most of my career, although I did…

clinical research Clinical research and access are the name of the game. The Executive Director of the association bringing together the most important research-based pharmaceutical companies discusses how the association has stepped up to partner up with the government and stakeholders to fight for the same objective and create a better health…

clinical research Liz Chatwin came to Korea as general manager of AstraZeneca in the fall of 2013, following a period working at the company’s Chinese affiliate for several years. She contrasts the two markets and highlights the unprecedented quality of Korea’s clinical research capacity. What were your initial impressions of the market…

clinical trials The country manager of a British biopharmaceutical company sheds light on Algeria’s potential for conducting clinical trials and offers his views on the quality of the country’s skilled labour. What is the record of your past fourteen months with AstraZeneca? Since I arrived, I have had two priorities. First, I implemented a new…

clinical trials The general manager of a leading British research-based pharmaceutical company discusses Algeria’s suitability as a destination for pre-clinical and clinical trials and assesses the country’s ability to transition from importer to local producer status Can you please start by briefly introducing GSK in Algeria? GSK activities in Algeria span three…